Objective To ivsetigate the clinical effect and safety of early application of load dose of atorvastation to patients with non-ST-segment elevation acute myocardial infarction with nornal lipids. Methods A total of 65 patients who were diagnosed as having NSTEMI with nornal lipids were randomly divided into atorvastation load dose group (group A, n=33) and the conventional dose group (group B, n=32).Group A took 40 mg/d atorvastation in addition to routine treatment.Group B took 20 mg/d atorvastation.Blood lipids, high-sensitivity C-reactive protein(hs-CRP)and adiponectin(APN) levels, and liver functions were measured before treatment and after 2 weeks of treatment.Patients were followed up for 6 months. The incidence of major adverse cardiovascular events(MACE) were observed. Results The TCH,LDL-C and hs-CRP levels were decreased more obviously in group A after 2 weeks treatment (P＜0.05).while the APN levels were increased more obviously in group A(P＜0.05).Obvious liver dysfunctions were not found in both groups. After 6 months,the incidence of MACE was lower in group A than in group B. Conclusions In patients with NSTEMI, even with normal blood lipids,taking load dose of atorvastation early can reduce the inflammation response, improve the stabilization of atherosclerotic plaque and improve the prognosis.